Poor
Not Aligned
Patient Risk:
High
Summary
Most claims are not supported by the provided FDA label excerpts, which only include general geriatric caution and several drug-interaction sections unrelated to metoprolol. No metoprolol-specific or many safety-risk claims (kidney/GI/fluid retention, heart failure, uncontrolled hypertension, dehydration) are supported by the supplied label text.
Category Scores
Accurate Statements
Age over 65 increases risks associated with ibuprofen use.
GERIATRIC USE: "caution should be exercised in treating the elderly (65 years and older)."
Unsupported Statements
Ibuprofen is generally not recommended to be taken with metoprolol without consulting a doctor.
No provided label text addresses metoprolol or gives this recommendation.
Ibuprofen can reduce metoprolol's blood pressure-lowering effect by interfering with its antihypertensive action.
No provided label text addresses metoprolol or antihypertensive effect interference.
The interaction between ibuprofen and metoprolol increases blood pressure control risks, especially in patients with hypertension or heart conditions.
No provided label text addresses metoprolol or these patient-risk framing elements.
Combining ibuprofen with metoprolol may blunt metoprolol's effectiveness.
No provided label text addresses metoprolol effectiveness.
Combining ibuprofen with metoprolol may lead to higher blood pressure or worsening heart failure symptoms.
No provided label text addresses metoprolol or heart failure worsening in this context.
Long-term ibuprofen/NSAID use increases risks of kidney issues.
No provided label excerpt in the prompt supports this specific long-term kidney-risk claim.
Long-term ibuprofen/NSAID use increases risks of stomach ulcers.
No provided label excerpt in the prompt supports this specific long-term GI ulcer claim.
Long-term ibuprofen/NSAID use increases risks of fluid retention.
No provided label excerpt in the prompt supports this specific fluid retention claim.
Short-term ibuprofen use might be tolerated under medical supervision.
No provided label excerpt supports this short-term/tolerated-if-supervised statement.
Ibuprofen is an NSAID.
No provided label excerpt explicitly states this within the supplied sections.
Safe use of ibuprofen is possible in rare cases if a doctor approves low-dose, short-term ibuprofen while monitoring blood pressure and kidney function.
No provided label excerpt supports this conditional 'rare cases' framing or the specific monitoring guidance.
Ibuprofen should be avoided if the patient has kidney disease.
No provided label excerpt in the prompt includes this contraindication/avoidance statement.
Ibuprofen should be avoided if the patient has heart failure.
No provided label excerpt in the prompt includes this contraindication/avoidance statement.
Ibuprofen should be avoided if the patient has uncontrolled hypertension.
No provided label excerpt in the prompt includes this contraindication/avoidance statement.
The American Heart Association and FDA warn against routine NSAID use with beta-blockers like metoprolol due to reduced efficacy and cardiovascular risks.
No provided FDA label excerpt supports this statement, and no such warning appears in the prompt-supplied text.
Studies confirm that concurrent use of NSAIDs with beta-blockers like metoprolol can cause a 20–30% drop in blood pressure control.
No provided label excerpt supports the existence of a metoprolol/beta-blocker interaction or provides this quantitative effect.
Avoid other NSAIDs like naproxen or diclofenac when using metoprolol.
No provided label excerpt supports avoiding other NSAIDs specifically when using metoprolol.
Dehydration heightens risks associated with ibuprofen use.
No provided label excerpt in the prompt supports dehydration as a risk modifier.
Contradictions
Important Omissions
Any FDA label-supported guidance specific to metoprolol (beta-blocker) coadministration, including whether metoprolol is affected and any recommended avoidance/monitoring.
Importance:
High
Label-supported renal/GI/cardiovascular risk statements and long-term risk language (e.g., what to monitor, which warnings apply) corresponding to the claims made.
Importance:
Moderate
Label-supported basis for any 'avoid' recommendations in populations stated (kidney disease, heart failure, uncontrolled hypertension).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Claims include multiple specific safety/interaction and avoidance statements (metoprolol effectiveness, blood pressure, heart failure worsening, kidney/GI risks, dehydration) that are not supported by the provided FDA label excerpts, creating substantial risk of misinformation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Metoprolol-specific interaction and multiple NSAID risk/avoidance claims are unsupported by the supplied label text; only geriatric caution (age ≥65) is partially supported.
Suggested Improvement
Remove or revise metoprolol/beta-blocker and quantitative interaction claims unless corresponding FDA label text is provided. Restrict statements to the provided label excerpts (e.g., geriatric caution) and to supported interaction categories shown (ACE-inhibitors, aspirin, diuretics, lithium, methotrexate, warfarin-type anticoagulants, H2 antagonists) rather than metoprolol.